Active	Status	Sponsor type	Region	Phase	Filter
8 Active 4 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Michl, Patrick
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors	Active, not recruiting	2	352	Europe, Canada, US	tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin	Seagen Inc., Genmab, Merck Sharp & Dohme LLC	Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck	02/26	11/26
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)	Completed	N/A	400	Europe	FoundationOne®CDx and FoundationOne®Liquid	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG	Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer	08/24	08/24
PLATON, NCT05489250: The Network	Active, not recruiting	N/A	1000	Europe		Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer	05/32	05/32
RINKE, Anja
CABONEN, NCT04524208: A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3	Active, not recruiting	2	45	Europe	Cabozantinib	Karsten Gavenis	Neuroendocrine Tumors, Neuroendocrine Carcinoma	09/24	10/24
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)	Completed	N/A	400	Europe	FoundationOne®CDx and FoundationOne®Liquid	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG	Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer	08/24	08/24
Zumblick, Malte
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)	Completed	N/A	400	Europe	FoundationOne®CDx and FoundationOne®Liquid	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG	Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer	08/24	08/24
Gehring, Sonja
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)	Completed	N/A	400	Europe	FoundationOne®CDx and FoundationOne®Liquid	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG	Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer	08/24	08/24
Skerra, Juliane
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)	Completed	N/A	400	Europe	FoundationOne®CDx and FoundationOne®Liquid	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG	Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer	08/24	08/24